A Rashid1, M Zahurak, S N Goodman, S R Hamilton. 1. Division of Gastrointestinal/Liver Pathology, Department of Pathology, Ross Building Room 632, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205-2196, USA.
Abstract
BACKGROUND: The genetic epidemiology of colorectal adenomas has not been studied prospectively in colonoscopy patients without cancer. AIMS: To study genetic alterations in colorectal adenomas and correlate these with patient demographics and adenoma characteristics. METHODS: Mutations and allelic deletions in 201 adenomas from 60 patients were compared with demographic features, adenoma characteristics, and family history. RESULTS: The most common alteration was K-ras proto-oncogene mutation, present in 35% of adenomas and 65% of patients. Patients 65 years of age and older had a decreased probability of K-ras mutations (26% versus 45%). Overexpression of p53 gene product was present in only 6% of adenomas but was more frequent in villous or tubulovillous adenomas (19% versus 3%). Allelic loss of chromosome 18q was present in only 2% of adenomas and was significantly less frequent than p53 overexpression. DNA replication errors (RER) were present in 7% of adenomas and 15% of patients, including multiple adenomas in four patients (two with hereditary non-polyposis colorectal cancer syndrome). Only 36% of RER positive adenomas had alteration of BAT-26 alleles, none had alteration of BAT-25, and only one (8%) had mutation in the transforming growth factor beta type II receptor gene. RER positive adenomas were more likely to have a K-ras mutation. In patients with multiple adenomas, there was concordance of p53 overexpression and RER but not of K-ras mutations. CONCLUSIONS: Genetic progression in colorectal adenomas is heterogeneous, involving factors related to patient age and the presence of RER for the occurrence of ras mutations, but different intraindividual characteristics for the occurrence of p53 alterations and RER.
BACKGROUND: The genetic epidemiology of colorectal adenomas has not been studied prospectively in colonoscopy patients without cancer. AIMS: To study genetic alterations in colorectal adenomas and correlate these with patient demographics and adenoma characteristics. METHODS: Mutations and allelic deletions in 201 adenomas from 60 patients were compared with demographic features, adenoma characteristics, and family history. RESULTS: The most common alteration was K-ras proto-oncogene mutation, present in 35% of adenomas and 65% of patients. Patients 65 years of age and older had a decreased probability of K-ras mutations (26% versus 45%). Overexpression of p53 gene product was present in only 6% of adenomas but was more frequent in villous or tubulovillous adenomas (19% versus 3%). Allelic loss of chromosome 18q was present in only 2% of adenomas and was significantly less frequent than p53 overexpression. DNA replication errors (RER) were present in 7% of adenomas and 15% of patients, including multiple adenomas in four patients (two with hereditary non-polyposis colorectal cancer syndrome). Only 36% of RER positive adenomas had alteration of BAT-26 alleles, none had alteration of BAT-25, and only one (8%) had mutation in the transforming growth factor beta type II receptor gene. RER positive adenomas were more likely to have a K-ras mutation. In patients with multiple adenomas, there was concordance of p53 overexpression and RER but not of K-ras mutations. CONCLUSIONS: Genetic progression in colorectal adenomas is heterogeneous, involving factors related to patient age and the presence of RER for the occurrence of ras mutations, but different intraindividual characteristics for the occurrence of p53 alterations and RER.
Authors: M Konishi; R Kikuchi-Yanoshita; K Tanaka; M Muraoka; A Onda; Y Okumura; N Kishi; T Iwama; T Mori; M Koike; K Ushio; M Chiba; S Nomizu; F Konishi; J Utsunomiya; M Miyaki Journal: Gastroenterology Date: 1996-08 Impact factor: 22.682
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler Journal: Nature Date: 1992-09-17 Impact factor: 49.962
Authors: M Miyaki; M Seki; M Okamoto; A Yamanaka; Y Maeda; K Tanaka; R Kikuchi; T Iwama; T Ikeuchi; A Tonomura Journal: Cancer Res Date: 1990-11-15 Impact factor: 12.701
Authors: Robert P Whitehead; Sheryl McCoy; John S Macdonald; Saul E Rivkin; Marcus A Neubauer; Shaker R Dakhil; Heinz-Josef Lenz; Michael S Tanaka; James L Abbruzzese Journal: Invest New Drugs Date: 2006-07 Impact factor: 3.850
Authors: Janine G Einspahr; Maria Elena Martinez; Ruiyun Jiang; Chiu-Hsieh Hsu; Asif Rashid; Achyut K Bhattacharrya; Dennis J Ahnen; Elizabeth T Jacobs; P Scott Houlihan; C Renee Webb; David S Alberts; Stanley R Hamilton Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-08 Impact factor: 4.254
Authors: David J Harriss; N Tim Cable; Keith George; Thomas Reilly; Andrew G Renehan; Najib Haboubi Journal: Sports Med Date: 2007 Impact factor: 11.136
Authors: Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell Journal: BMC Cancer Date: 2010-03-16 Impact factor: 4.430